This study is recruiting individuals between the ages of 12 and 35 who have been diagnosed with Type 1 Diabetes within the past 6 months. The study is seeking individuals who are still in the “honeymoon period.”

Eligible patients will be randomized to receive either placebo or CNP-103, the investigational study drug. Researchers are looking at whether CNP-103 can keep individuals from progressing past Stage 3 T1D. Once an individual progresses to Stage 4, the pancreas no longer produces any insulin.

The study lasts approximately 1 year and includes a Screening Visit to determine eligibility, and 9 additional visits over a 12-month time period.

Compensation is provided to participants.

If you fit this criteria, please fill out your information below, including when you were diagnosed with T1D. We will get back to you within 24-48 hours to share more information about the study. Thank you!